What this means
This is a planned trial that has not started enrolling people yet. It will compare exercise plus the drug against the drug alone, but no results exist yet.
Plain-English summary written by an AI model from the registry listing.
- Status
- Opening soon
- Who can join
- Ages 18–65 · 108 overweight or obese adults planned
- Where
- Not listed
The science
- Registered title
- Effectiveness of Combined GLP-1/GIP Dual Agonist Therapy and Structured Exercise on Skeletal Muscle Morphology, Quality, and Physical Function in Overweight and Obese Individuals
- Trial ID
- NCT07609160 ↗
- Phase
- Not applicable
- Study type
- interventional
- Conditions
- Obesity, Sarcopenia, Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities
- What is tested
- Resistance exercise, Lifestyle recommendations
- Sponsor
- Acibadem University
- Ages
- 18 Years to 65 Years
- Dates
- First posted May 27, 2026 · updated Jun 4, 2026
Registry summary
This randomized controlled trial aims to investigate the effects of a 24-week home-based progressive resistance exercise program combined with tirzepatide treatment on skeletal muscle mass, muscle quality, and functional capacity in overweight and obese individuals. A total of 108 participants initiating tirzepatide therapy will be randomized to either exercise plus pharmacotherapy or pharmacotherapy alone. The primary outcome is change in thigh muscle thickness and echo intensity assessed by ultrasonography.